Status:
COMPLETED
Haloperidol for the Treatment of Nausea and Vomiting in the ED
Lead Sponsor:
Western Michigan University School of Medicine
Conditions:
Vomiting
Nausea
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 prese...
Eligibility Criteria
Inclusion
- presenting to the emergency department with chief complaint of nausea or vomiting
Exclusion
- abnormal blood pressure (\>200/100mmHg or \<90/40mmHg),
- fever (\>100.4F),
- acute trauma,
- QT \> 450ms on cardiac monitor,
- altered mental status (GCS \< 15),
- chest pain,
- known allergy to haloperidol or ondansetron,
- Parkinson's disease,
- pregnancy or lactation,
- use of any antiemetic in the previous 8 hours,
- nausea and vomiting associated with vertigo,
- prisoners or any wards of the state.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 22 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04764344
Start Date
April 1 2021
End Date
May 22 2023
Last Update
June 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bronson Methodist Hospital
Kalamazoo, Michigan, United States, 49007